UV-spectrophotometric determination of imatinib mesylate and its application in solubility studies

被引:20
作者
Bende, G. [1 ]
Kollipara, S. [1 ]
Sekar, V. [1 ]
Saha, R. [1 ]
机构
[1] Birla Inst Technol & Sci, Formulat Dev & Pharmacokinet Lab, Fac Div 3, Pharm Grp, Pilani 333031, Rajasthan, India
来源
PHARMAZIE | 2008年 / 63卷 / 09期
关键词
D O I
10.1691/ph.2008.8094
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
A new, simple and sensitive UV-spectrophotometric method was developed for the determination of imatinib mesylate in bulk and pharmaceutical formulations (tablets and nanoparticles). The developed spectroscopic method was validated for selectivity, linearity and range, precision, accuracy and sensitivity. The method has demonstrated excellent linearity over the range of 2.5-25 mu g/mL with regression equation: absorbance (AU) = 0.047 x concentration (mu g/mL) + 0.008 and r(2) = 0.9998. The developed method demonstrated consistent high recoveries (99-102%) and low relative standard deviation (< 5%) at 285 nm. Moreover, the method was found to be highly sensitive with low limit of detection (0.57 mu g/mL) and limit of quantitation (1.71 mu g/mL). The apparent molar absorptivity and Sandell's sensitivity was found to be 2.75 x 10(3) L/M cm and 2.15 mu g/cm(2) respectively. The validated method was successfully employed for the drug content analysis from tablets and nanoparticles preparations. Additionally, the method was successfully employed for pH metric solubility analysis of the drug.
引用
收藏
页码:641 / 645
页数:5
相关论文
共 17 条
[1]
Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[2]
Protein kinases as drug targets in cancer [J].
Arslan, Mehmet Alper ;
Kutuk, Ozgur ;
Basaga, Huveyda .
CURRENT CANCER DRUG TARGETS, 2006, 6 (07) :623-634
[3]
High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media [J].
Bard, Bruno ;
Martel, Sophie ;
Carrupt, Pierre-Alain .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 33 (03) :230-240
[4]
Development and validation of a stability indicating RP-LC method for determination of imatinib mesylate [J].
Bende, Girish ;
Kollipara, Sivacharan ;
Kolachina, Venugopal ;
Saham, Ranendra .
CHROMATOGRAPHIA, 2007, 66 (11-12) :859-866
[5]
BOLTON S, 2004, PHARM STAT PRACTICAL, P216
[6]
Imatinib as a paradigm of targeted therapies [J].
Druker, BJ .
ADVANCES IN CANCER RESEARCH, VOL 91, 2004, 91 :1-+
[7]
ST1571 (Gleevec™) as a paradigm for cancer therapy [J].
Druker, BJ .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S14-S18
[8]
Imatinib (Gleevec®, Glivec®) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry [J].
Guetens, G ;
Prenen, H ;
De Boeck, G ;
Highley, M ;
de Wever, I ;
van Oosterom, AT ;
de Bruijn, EA .
JOURNAL OF SEPARATION SCIENCE, 2006, 29 (03) :453-459
[9]
FDA licences imatinib mesylate for CML [J].
Habeck, M .
LANCET ONCOLOGY, 2002, 3 (01) :6-6
[10]
*ICH COMM, 2005, INT C HARM TECHN REQ